A study involving 97,464 adults with type 2 diabetes found no increased risk of pancreatic cancer among those using semaglutide—marketed as Ozempic and Wegovy—compared to patients on other diabetes medications. The research, presented at this week’s European Association for the Study of Diabetes meeting in Milan, directly addresses a long-standing concern about these widely prescribed drugs.
The analysis combined data from Denmark, Sweden, and Norway, matching patients who began semaglutide with those using sulfonylureas, SGLT-2 inhibitors, or insulin. After a one-year waiting period to rule out pre-existing cancers, researchers tracked outcomes over an average of 1.4 to 1.85 years. Among semaglutide users, 131 pancreatic cancer cases emerged, while the comparison group saw 123. Statistical modeling produced a hazard ratio of 0.91, with a confidence interval spanning 0.71 to 1.16, indicating results could reflect random variation rather than a true effect.
In practical terms, semaglutide users experienced roughly 0.1 fewer cases per 1,000 person-years than the comparison group, a negligible difference that prevents any definitive conclusions about risk reduction or elevation. The study’s observational design and short follow-up period limit its ability to detect cancers that may develop over years. Regulators mandated this safety review following earlier concerns about GLP-1 drugs and pancreatic cancer.
Acute pancreatitis risk remains a concern
The findings offer partial reassurance for patients but do not resolve all uncertainties. Semaglutide remains approved for type 2 diabetes, yet the study excluded individuals using Wegovy for weight loss without diabetes, a growing user group. Funding came from Novo Nordisk, the manufacturer of both drugs, and the research has not yet undergone peer review.
A separate safety warning persists. While pancreatic cancer risk appears unchanged, acute pancreatitis, a painful pancreatic inflammation, remains linked to GLP-1 drugs. The U.S. Food and Drug Administration’s Ozempic prescribing information continues to list it as a risk. Patients should recognize its symptoms: severe upper abdominal pain radiating to the back, fever, nausea, vomiting, rapid heartbeat, or a swollen abdomen. Mild nausea is common when starting or adjusting doses, but worsening symptoms require urgent medical attention.
Read Also: Mezzetta recalls peperoncini jars after pest found in jar
Individuals with a history of pancreatitis, gallstones, or heavy alcohol use face higher baseline risk. Professor Anton Pottegård of the University of Southern Denmark, who presented the work, said the findings “further strengthen the evidence that semaglutide does not increase the risk of pancreatic cancer.” However, the brief follow-up leaves unresolved questions about long-term use.
Short-term data leave long-term questions unanswered
For now, the data suggest no short-term cancer risk increase, though the full picture requires additional research. Journal publication and extended tracking will determine whether this pattern holds over time. The study’s one-year lag before tracking began aimed to exclude pre-existing cancers, but pancreatic cancer often develops over years. Even if semaglutide carries no heightened risk, the study’s duration may be insufficient to confirm this.
Registry data lack detailed patient information, such as lifestyle factors that could influence outcomes. Patients should not alter treatment based solely on this study, as abrupt changes may disrupt blood sugar control. Cost and access also shape these decisions. Switching drugs because of fear can trigger new insurance approvals and out-of-pocket costs, while staying on a working treatment avoids that disruption. Keeping a simple log of new abdominal symptoms can help a doctor sort ordinary side effects from warning signs.
The study’s results were consistent across all three Nordic countries. In Denmark, the hazard ratio for pancreatic cancer among semaglutide users was 0.92, with a confidence interval of 0.67 to 1.27. Sweden’s ratio was 0.87 (0.59 to 1.29), and Norway’s was 0.95 (0.67 to 1.36). These variations, all within expected ranges, support the overall conclusion that semaglutide use did not raise pancreatic cancer risk in any country.
Researchers also assessed whether higher doses or longer treatment durations affected outcomes. The data showed no link between cumulative semaglutide exposure and increased pancreatic cancer cases. Patients using the drug for up to two years, after the one-year exclusion period, demonstrated no higher risk than those on shorter courses.